KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Net Income (2016 - 2025)

Neogenomics' Net Income history spans 16 years, with the latest figure at -$9.9 million for Q4 2025.

  • For Q4 2025, Net Income rose 35.52% year-over-year to -$9.9 million; the TTM value through Dec 2025 reached -$108.0 million, down 37.22%, while the annual FY2025 figure was -$108.0 million, 37.22% down from the prior year.
  • Net Income reached -$9.9 million in Q4 2025 per NEO's latest filing, up from -$27.1 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $75.9 million in Q2 2021 to a low of -$49.4 million in Q1 2022.
  • Average Net Income over 5 years is -$21.4 million, with a median of -$23.5 million recorded in 2022.
  • The largest YoY upside for Net Income was 1211.86% in 2021 against a maximum downside of 895.78% in 2021.
  • A 5-year view of Net Income shows it stood at -$41.8 million in 2021, then soared by 45.67% to -$22.7 million in 2022, then soared by 36.85% to -$14.3 million in 2023, then dropped by 6.97% to -$15.3 million in 2024, then surged by 35.52% to -$9.9 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Net Income are -$9.9 million (Q4 2025), -$27.1 million (Q3 2025), and -$45.1 million (Q2 2025).